摘要
高级别胶质瘤(HGG)通常具有严重预后不良反应,在过去十年的治疗过程中引入烷基化剂替莫唑胺可适度改善。对MGMT(O-6甲基鸟嘌呤DNA-甲基转移酶)启动子甲基化状态为患者化疗反应最有效的预测及预后因素之一。例如,评估MGMT启动子状态的分子方法不规范。因此,我们开发了基于甲基化特异性-PCR的荧光毛细管凝胶电泳技术。 这种技术可进行甲基化和未甲基化的等位基因间相对比的半定量估计。在178HGG初诊成人患者中进行了功效和技术准确度的评估,并进行了均匀治疗的回顾性研究。首先,我们分析了MGMT启动子甲基化在不同的分界点生存的影响因素,我们进一步研究成人HGGs中甲基化和未甲基化的等位基因的不同比例与其他知名预后分子因素的关联性。这种方法可验证我们的技术非常灵敏(检测低甲基化百分比,<5%),说明其在新鲜冷冻及FFPE样品中检测肿瘤内的异质性是可行的。
关键词: 成体,高级别胶质瘤,PCR甲基化特异性,肿瘤异质性。
Current Cancer Drug Targets
Title:An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Volume: 15 Issue: 7
Author(s): Aurelia Nguyen, Michele Legrain, Georges Noel, Andres Coca, Nicolos Meyer(EA), Roland Schott, Christelle Lasthaus and Marie Pierrette Chenard, Marie Pierre Gaub, Jean Marc Lessinger, Dominique Guenot and Natacha Entz-Werle
Affiliation:
关键词: 成体,高级别胶质瘤,PCR甲基化特异性,肿瘤异质性。
摘要: High grade gliomas (HGG) are usually associated with a very dismal prognosis, which was moderately improving in the last decade with the introduction of the alkylating agent temozolomide in their treatment. The methylation status of MGMT (O6 methylguanine DNA-methyltransferase) promoter is one of the strongest predictive and prognostic factors for the patient chemoresponse. For instance, the molecular method of assessment for MGMT promoter status is not standardized. In this background, we developed a fluorescent capillary gel electrophoresis-based methylation specific-PCR.
This technique allowed a semi-quantitative estimate of the relative ratio between methylated and unmethylated alleles. The efficacy and accuracy of the technique was assessed in a retrospective cohort of 178 newly diagnosed adult HGGs, who were homogeneously treated. First, we analyzed the impact on survival of different cut-off points in the MGMT promoter methylation and, to go further, we correlated these different rates to other well-known prognostic molecular factors involved in adult HGGs. This strategy allowed to validate our technique as a very sensitive technique (detection of a low methylation percentage, < 5%), which was feasible in fresh-frozen as well as in FFPE samples and had the propensity to detect intra-tumor heterogeneity.
This technique identified a new sub-group of anaplastic oligodendrogliomas or oligoastrocytomas defined by a minor methylation and a worse outcome and, therefore, will help to substratify accurately into more homogeneous subgroups of methylated tumors.
Export Options
About this article
Cite this article as:
Aurelia Nguyen, Michele Legrain, Georges Noel, Andres Coca, Nicolos Meyer(EA), Roland Schott, Christelle Lasthaus and Marie Pierrette Chenard, Marie Pierre Gaub, Jean Marc Lessinger, Dominique Guenot and Natacha Entz-Werle , An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150629130139
DOI https://dx.doi.org/10.2174/1568009615666150629130139 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Synergism of Temozolomide, Metformin, and Epigallocatechin Gallate Promotes Oxidative Stress-Induced Apoptosis in Glioma Cells
Current Drug Therapy Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Current Medicinal Chemistry Heterocyclic Nucleosides: Chemical Synthesis and Biological Properties
Current Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry